Page 10 - Sohini Das

Q1 results preview: Low volumes, discounts may have dented auto margins

Downside risks from rare-earth magnets an overhang for the sector

Valuation of Manipal Hospitals hits $13 billion; firm eyes IPO in 2026

Bengaluru-based Manipal Hospitals cements top spot with major expansion, aims IPO

Glenmark arm inks $700 million licensing deal with US-based AbbVie

IGI Therapeutics, a wholly owned subsidiary of Glenmark, has licensed its cancer and autoimmune drug ISB 2001 to AbbVie for an upfront payment of $700 million

No immediate production impact due to rare-earth crunch: JSW MG Motor

Company says parts pipeline remains steady for now as orders placed in April are arriving; rare-earth supply disruption remains under close watch for future impact

India's pharma exports to US surged in March amid tariff concerns

India's pharma exports saw a significant rise in March, driven by fears of impending US tariffs. Industry experts anticipate impact of potential reciprocal tariffs on India's future export strategy

Apollo AyurVAID aims for 1,000 beds by 2028, eyes ₹500 crore turnover

Apollo AyurVAID, one of India's largest Ayurvedic hospital chains, targets 1,000 beds and Rs 500 crore turnover by 2028, as demand for Ayurvedic treatments rises

Car price inflation may moderate 4.5% over 5 years as tech improves

While average selling prices rose 7.6% between 2019 and 2024 due to premiumisation and regulation costs, they are expected to rise more moderately at 4.5% CAGR till 2029

Luxury cars' share in EV sales up as uber rich shift to clean fuel

India's ultra-rich are embracing EVs, with the luxury electric segment growing 66% in 2025; Mercedes, BMW, Audi lead, aided by new launches and better charging infra

Torrent Pharma to acquire JB Pharma from KKR at ₹25,689 cr valuation

Torrent Pharma will acquire KKR's 46.39% stake in JB Pharma followed by open offer and merger, strengthening chronic segment and CDMO footprint in India and abroad

Torrent Pharma in advanced talks to acquire JB Chemicals from KKR

Torrent Pharma is negotiating to acquire JB Chemicals from KKR in a deal that may trigger an open offer, strengthening its position in the domestic pharma market

Mercedes-Benz India unfazed by China rare-earth magnets supply curbs

Company is 'comfortably placed' this year in sourcing critical supply, says automaker

Strong EV lineup pushes hybrids to the back seat; penetration hits 4.4%

EVs are taxed at 5% while hybrid vehicles attract an overall tax rate of 43%

Tata Motors plans new Ace diesel variant without DEF, targets SCV recovery

Tata Motors plans to reintroduce its Ace diesel mini-truck without SCR tech to reduce total cost of ownership, while expanding rural presence with Intra range

Tata Motors has 'comfortable' stocks, supplies of rare-earth magnets

Company open to hybrids if market demands but thinks it is not a destination tech

No sign of panic among Indian exporters; shift to Cape of Good Hope route

Despite Iran-Israel instability, exporters report no disruption in trade as 96 per cent of India's container traffic shifts to the Cape of Good Hope route

Amazon enters India's $15 bn diagnostics market with at-home testing

Amazon enters India's $15 bn diagnostics sector with at-home test collection, digital reports and integrated health services through Amazon Medical across six cities

Decision on merger with Biocon Biologics soon, says Siddharth Mittal

We are talking about the GLP-1 opportunity and our strong franchise in insulins. There is a huge demand in the global diabetes-obesity segment, said Siddharth Mittal

Tata Motors expects to achieve 30% EV penetration ahead of target: Chandra

Looking for alternative sourcing for Rare earth magnets and focussing on right level of inventory, Chandra says

Pharma manufacturing tends to cause AMR in communities: Nick Voulvoulis

Changes are required both in manufacturing practices as well as in regulatory oversight, says Voulvoulis

Abbott, MSD join hands to distribute key diabetic drug across India

Abbott to distribute MSD's sitagliptin portfolio-Januvia, Janumet, Janumet XR-in India, targeting deeper reach in the ₹950-1,000 crore diabetes drug segment